New hope for myeloma: adaptive trial tests smarter drug combos
Disease control
Ongoing
This phase II trial is testing new therapies, including the drug teclistamab, for people with multiple myeloma that has relapsed or not responded to treatment. About 300 participants will be enrolled in an adaptive platform design that allows adding new treatment arms over time. …
Phase: PHASE2 • Sponsor: Multiple Myeloma Research Consortium • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC